Beyond weight loss: tirzepatide as a dual GIP/GLP-1 receptor agonist for obstructive sleep apnea
As a dual GIP/GLP-1 RA, tirzepatide represents a promising therapy for OSA in individuals with obesity, offering benefits of both weight reduction and symptom improvement. Given the high burden and underdiagnosis of OSA, particularly in populations with obesity, it should be considered earlier in the treatment algorithm, either in combination with or as an alternative to traditional therapies.
Authors
- Jairo Noreña
- Tugce Akcan (ORCID: https://orcid.org/0000-0003-4320-222X)
- Dimpi Desai (ORCID: https://orcid.org/0000-0003-1420-4357)
Institutions
- Alameda Health System (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- Current Opinion in Endocrinology Diabetes and Obesity
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1097/med.0000000000000949
- Primary Topic
- Obstructive Sleep Apnea Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00